What is the recommended interval between seton placement and initiation of infliximab in patients with complex perianal CD

What is known

- In a pediatric systematic review setons were placed before infliximab induction, with infliximab started at a median of ~3 months after seton placement and setons kept a median of 8 months. ¹ - Cohort protocols describe inserting drainage setons at the pre-infliximab EUA, then starting induction infusions and removing the seton after the second infusion. ² - Current guidelines generally recommend initial EUA with drainage/loose setons followed by anti-TNF (infliximab first-line), but with considerable variability in surgical timing. ³ - Guideline recommendations on timing of seton removal relative to anti-TNF ranged from predefined intervals after therapy initiation to individualized clinical/radiologic criteria. ³

What is unknown / caveats

- One study explicitly evaluated early vs late seton-plus-infliximab timing, implying no settled optimum - Evidence is largely retrospective cohorts, a pediatric SR, and narrative reviews — no RCT defines an optimal seton-to-infliximab interval - Reported intervals describe practice, not validated thresholds - The excerpts do not converge on a recommended fixed interval between seton placement and infliximab initiation.

## References

1. Kantor N, Wayne C, Nasr A. What is the optimal surgical strategy for complex perianal fistulous disease in pediatric Crohn's disease? A systematic review. Pediatr Surg Int. 2017;33(5):551-557. PMID: 28138950.

2. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49(12):1837-41. PMID: 17041753.

3. Medawar E, Chaudhary H, Zoughlami A, Ekhdoura M, Safih W, Gupta S, Wong SY, Deepak P, Hart A, Tozer P, McCurdy JD. Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease. Aliment Pharmacol Ther. 2026;63(7):932-944. PMID: 41693361.

For educational use only — not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft — generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._